Multicenter study on Clostridioides difficile infections in Mexico: exploring the landscape.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De-la-Rosa-Martinez Daniel, Vilar-Compte Diana, Martínez-Rivera Nancy, Ochoa-Hein Eric, Morfin-Otero Rayo, Rangel-Ramírez María Esther, Garciadiego-Fossas Pamela, Mosqueda-Gómez Juan Luis, Rodríguez Zulueta Ana Patricia, Medina-Piñón Isaí, Franco-Cendejas Rafael, Alfaro-Rivera Christian Gerardo, Rivera-Martínez Norma Eréndira, Mendoza-Barragán Jonathan, López-Romo Alicia Estela, Manríquez-Reyes Marisol, Martínez-Oliva David Humberto, Flores-Treviño Samantha, Azamar-Marquez Jhoan M, Valverde-Ramos Lirio Nathali, Nieto-Saucedo José Raúl, Aguirre-Díaz Sara Alejandra, Camacho-Ortiz Adrián, Mexican C. difficile Study Group
Аннотация
DESIGN: Observational study of case series.
SETTING: Sixteen public hospitals and private academic healthcare institutions across eight states in Mexico from January 2016 to December 2022.
PATIENTS: CDI patients.
METHODS: Demographic, clinical, and laboratory data of CDI patients were obtained from clinical records. Cases were classified as community or healthcare-associated infections, with incidence rates calculated as cases per 10,000 patient days. Risk factors for 30-day all-cause mortality were analyzed by multivariate logistic regression.
RESULTS: We identified 2,356 CDI cases: 2,118 (90%) were healthcare-associated, and 232 (10%) were community-associated. Common comorbidities included hypertension, diabetes, and cancer. Previous high use of proton-pump inhibitors, steroids, and antibiotics was observed. Recurrent infection occurred in 112 (5%) patients, and 30-day mortality in 371 (16%). Risk factors associated with death were a high Charlson score, prior use of steroids, concomitant use of antibiotics, leukopenia, leukocytosis, elevated serum creatine, hypoalbuminemia, septic shock or abdominal sepsis, and SARS-CoV-2 coinfection. The healthcare-associated CDI incidence remained stable at 4.78 cases per 10,000 patient days during the pre-and pandemic periods. However, the incidence was higher in public hospitals.
CONCLUSIONS: Our study underscores the need for routine epidemiology surveillance and standardized CDI classification protocols in Mexican institutions. Though CDI rates in our country align with those in some European countries, disparities between public and private healthcare sectors emphasize the importance of targeted interventions.